Larimar Therapeutics (LRMR) Operating Margin: 2014-2020
Historic Operating Margin for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to 1,183.72%.
- Larimar Therapeutics' Operating Margin fell 147168.00% to 1,183.72% in Q1 2020 from the same period last year, while for Mar 2020 it was 2,293.55%, marking a year-over-year decrease of 73206.00%. This contributed to the annual value of 2,585.16% for FY2019, which is 63517.00% down from last year.
- Per Larimar Therapeutics' latest filing, its Operating Margin stood at 1,183.72% for Q1 2020, which was down 41.15% from 2,011.33% recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' Operating Margin ranged from a high of 166,975.00% in Q4 2017 and a low of 1,183.72% during Q1 2020.
- Its 3-year average for Operating Margin is 2,703.92%, with a median of 2,944.09% in 2018.
- As far as peak fluctuations go, Larimar Therapeutics' Operating Margin skyrocketed by 15,617,603bps in 2017, and later plummeted by 16,403,091bps in 2018.
- Larimar Therapeutics' Operating Margin (Quarterly) stood at 10,798.97% in 2016, then spiked by 15,617,603bps to 166,975.00% in 2017, then tumbled by 16,403,091bps to 2,944.09% in 2018, then tumbled by 93,276bps to 2,011.33% in 2019, then slumped by 147,168bps to 1,183.72% in 2020.
- Its Operating Margin was 1,183.72% in Q1 2020, compared to 2,011.33% in Q4 2019 and 3,029.58% in Q3 2019.